key: cord-0959489-x9rs7ak7
authors: Xie, Yuanchao; Yin, Wanchao; Zhang, Yumin; Shang, Weijuan; Wang, Zhen; Luan, Xiaodong; Tian, Guanghui; Aisa, Haji A.; Xu, Yechun; Xiao, Gengfu; Li, Jia; Jiang, Hualiang; Zhang, Shuyang; Zhang, Leike; Xu, H. Eric; Shen, Jingshan
title: Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2
date: 2021-09-28
journal: Cell Res
DOI: 10.1038/s41422-021-00570-1
sha: 20df22505f17bea74edc4498205ad55e9233cbca
doc_id: 959489
cord_uid: x9rs7ak7

nan

assay recorded the synthesis of dsRNA in a reaction using a self-primer RNA as a template and ATP as the natural substrate, and the self-primer RNA was synthesized 

The BALB/c mice were bred and maintained in specific pathogen free (SPF) environment at the Laboratory Animal Center of Wuhan Institute of Virology, CAS.

Female mice at six to eight weeks-old were used in our study. The animal experiments were conformed to the use and care of laboratory animals and approved by the Institutional Review Board of the Wuhan Institute of Virology, CAS.

Animals were divided into six groups (n = 10 for each group), the vehicle group, the 

The preclinical PK studies of VV116 in two species (SD rats and Beagle dogs) were conducted at Suzhou HQ Bioscience Co., Ltd. according to the NMPA "Guidelines for Nonclinical Pharmacokinetics studies", May 2014.

The PK study in SD rats: 30 animals divided into five groups (N = 6 for each group with 3 male and 3 female) were fasted for 12 h before dosing. Animals in Group 1 were administered intravenously with VV116 (dissolved in DMSO/EtOH/PEG300/0.9%NaCl, 

Thirty SD rats were randomly divided into five groups (n = 6, half male and half male). All rats were intragastrically administered with a single dose of 30 mg/kg VV116. At 0, 0.25, 2, 6, 24 h post-dosing, the rats were anesthetized, and tissues including brain, heart, liver, spleen, lung, kidney, pancreas, testis, ovaries, uterus, stomach, small intestine, adrenal gland, skin, thymus, skeletal muscle, and abdominal adipose tissue were harvested. Blood samples were collected, and part of them were centrifuged to obtain the plasma. Tissue samples were individually homogenized, and the concentrations of X1 in plasma, whole blood and tissue homogenates were analyzed by LC-MS/MS.

Metabolites of VV116 in SD rats (plasma, urine, feces and bile) and in Beagle dogs (plasma)

were analyzed by UPLC-UV/Q-TOFMS after a single intragastric administration of VV116.

The bile, urine and feces samples of rats were obtained in the excretion study; the rat plasma sample was obtained in the tissue distribution study, and the plasma sample of Beagle dogs was obtained in the PK study.

The single dose oral toxicity study and the 14-day repeated dose oral toxicity study in two species (SD rats and beagle dogs) were conducted at Center of Drug Safety Evaluation In this study, the NOAEL was 30 mg/Kg.

A7 and A10 are known compounds, which could be synthesized according to the reported methods 2,3 , and the synthesis of other compounds was reported elsewhere 4 .

The materials and reagents were commercially available and solvents, if necessary, were purified and dried by standard methods. 1 Compound 1-2 (1.77 g, 2.57 mmol) was added to anhydrous tetrahydrofuran (20 mL) and deuteroxide (2 mL), and then the solvent was removed in vacuum. The procedure was repeated, followed by addition of tetrahydrofuran (20 mL) and deuteroxide (2 mL) again.

To this solution were added 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.11 g, 0.13 mmol) and N,N,N',N'-tetramethylethylenediamine (0.60 g, 5.14 mmol). After stirring for 10 min at room temperature, sodium borodeuteride (0.22 g, 5.14 mmol) was added in portion within 30 min. The mixture continued to be stirred at room temperature until the starting material disappeared completely. Then, the reaction was quenched with saturated NH4Cl solution, and extracted with ethyl acetate. The organic phase was washed with brine, dried over Na2SO4, and concentrated. The residue was purified by chromatography on silica gel to give compound 1-3 with a deuterium content ≥ 98% as a white solid (0.79 g, yield 55%). 

Compound X1 (145 mg, 0.5 mmol) was added in pyridine (5 mL To a solution of compound 3-4 (289 mg, 0.48 mmol) and acetic acid (7 mg, 0.12 mmol) in tetrahydrofuran (10 mL), 1 M solution of tetrabutylammonium fluoride in THF (0.48 mL, 0.48 mmol) was added in an ice bath. The mixture was stirred for 2-3 h, then poured into water, and extracted with isopropyl acetate. The organic layer was separated, washed with saturated sodium bicarbonate and brine, then dried over Na2SO4 and evaporated. The crude product was slurried in n-heptane/isopropanol, and the resulting precipitate was filtrated to give compound X3 as a white solid (121 mg, yield 70%). 1 

To a solution of X1 (0.58 g, 2.0 mmol) in DMF (10 mL) was added N,N-dimethylformamide dimethyl acetal (1.43 g, 12.0 mmol) at room temperature. The mixture was stirred at 60 °C for 2 h, then cooled to room temperature, and an equivalent volume of methanol was added.

The solvent was evaporated under vacuum to give an oily residue which was treated with isopropyl alcohol. The resulting precipitate was collected by filtration and dried to give NaHCO3 aqueous solution and brine, dried over Na2SO4, and concentrated. The crude product 4-3 was used for the next step without purification.

To a solution of the crude product 4-3 in THF (30 mL), acetic acid (0.11 g, 1.75 mmol) and

1M tetrabutylammonium fluoride THF solution (3.5 mL, 3.5 mmol) were added at room temperature. The mixture was stirred for 2 h, and partitioned between ethyl acetate and water. The organic layer was washed with saturated NaHCO3 aqueous solution and brine, dried over Na2SO4, and concentrated. The crude product 4-4 was used for the next step without purification. 

To a solution of X6 (12.0 g, 23.9 mmol) in acetonitrile (100 mL), 40 wt.% hydrobromic acid in H2O (4.37 g, 21.6 mmol) was slowly added in an ice bath. After the addition, the mixture was allowed to warm to room temperature and continued to be stirred for 30 mins. The solvent was removed in vacuum, followed by the addition of methyl tert-butyl ether (150 mL). The mixture was stirred for 30 mins at room temperature, then stirred for 2 h at 55 °C, and cooled to room temperature. The solid was collected by filtration, and dried to give a white solid (10.8 g, yield 78%). 1 a Scored on a scale of 0-3: "0" = none or few, "1" = mild, "2" = moderate, and "3" = severe X1 after a single i.v. dose (10 mg/kg) of VV116 in SD rats (N = 6 per group). 

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

2'-Fluoro substituted carba-nucleoside analogs for antiviral treatment

Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

 Table S3 : Single-dose PK parameters for X1 in rats (for screening). Calculation of PK parameters for X1 following oral administration of X2, X3 or X6 at 10.0 mg/kg X1 equivalent dose, and intravenous administration at 2.0 mg/kg X1 equivalent dose in SD rats (N = 3 per group).

Cmax